Interestingly, the authors find that the anti-tumor effect of Tasquinimod is conserved in TLR4-deficient mice, indicating that Tasquinimod effect might be due to blocking S100A9-signaling through other receptors, or potentially to additional, yet unidentified mechanisms (39). This evidence concerns the gene TLR4 and neoplasm.